Sunzen Biotech Bhd Stock Current Valuation
| 0148 Stock | 0.32 0.01 3.23% |
Valuation analysis of Sunzen Biotech Bhd helps investors to measure Sunzen Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Sunzen Biotech's price fluctuation is extremely dangerous at this time. Calculation of the real value of Sunzen Biotech Bhd is based on 3 months time horizon. Increasing Sunzen Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sunzen stock is determined by what a typical buyer is willing to pay for full or partial control of Sunzen Biotech Bhd. Since Sunzen Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sunzen Stock. However, Sunzen Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.32 | Real 0.3 | Hype 0.32 | Naive 0.32 |
The intrinsic value of Sunzen Biotech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Sunzen Biotech's stock price.
Estimating the potential upside or downside of Sunzen Biotech Bhd helps investors to forecast how Sunzen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sunzen Biotech more accurately as focusing exclusively on Sunzen Biotech's fundamentals will not take into account other important factors: Sunzen Biotech Bhd Company Current Valuation Analysis
Sunzen Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sunzen Biotech Current Valuation | 128.73 M |
Most of Sunzen Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunzen Biotech Bhd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sunzen Biotech Bhd has a Current Valuation of 128.73 M. This is much higher than that of the Consumer Non-Cyclicals sector and significantly higher than that of the Food & Tobacco industry. The current valuation for all Malaysia stocks is notably lower than that of the firm.
Sunzen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunzen Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunzen Biotech could also be used in its relative valuation, which is a method of valuing Sunzen Biotech by comparing valuation metrics of similar companies.Sunzen Biotech is currently under evaluation in current valuation category among its peers.
Sunzen Fundamentals
| Return On Equity | 2.91 | |||
| Current Valuation | 128.73 M | |||
| Price To Book | 1.22 X | |||
| Price To Sales | 1.34 X | |||
| Revenue | 90.48 M | |||
| EBITDA | 6.57 M | |||
| Net Income | 3.71 M | |||
| Total Debt | 5.08 M | |||
| Cash Flow From Operations | (16.36 M) | |||
| Market Capitalization | 147.73 M | |||
| Total Asset | 148.71 M | |||
| Z Score | 17.4 | |||
| Net Asset | 148.71 M |
About Sunzen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sunzen Biotech Bhd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunzen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunzen Biotech Bhd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Sunzen Stock
Sunzen Biotech financial ratios help investors to determine whether Sunzen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sunzen with respect to the benefits of owning Sunzen Biotech security.